{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T10:30:15Z","timestamp":1746786615653,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Patienten mit altersabh\u00e4ngiger Makuladegeneration (AMD) erhalten h\u00e4ufig zeitgleich systemische blutverd\u00fcnnende Medikamente. Diese erh\u00f6hen bekannterma\u00dfen das Risiko f\u00fcr schwere Blutungen, unter anderem auch im Rahmen der AMD, sodass es zu extensiven subretinalen Blutungen kommen kann.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel der Arbeit<\/jats:title>\n                <jats:p>In dieser Studie soll untersucht werden, wie hoch der Anteil an Patienten mit AMD und blutverd\u00fcnnender Therapie ist und welche blutverd\u00fcnnenden Medikamente eingenommen werden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>Diese Umfrage wurde prospektiv an der Universit\u00e4ts-Augenklinik Bonn durchgef\u00fchrt. Freiwillige wurden in der Netzhaut-Sprechstunde sowie der Sprechstunde f\u00fcr intravitreale Injektionen (IVOM) rekrutiert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Insgesamt konnten 178 Frageb\u00f6gen von 178 Patienten ausgewertet werden, bei denen der Fragebogen vollst\u00e4ndig ausgef\u00fcllt wurde. Das Durchschnittsalter betrug 81,7 Jahre (58 bis 100); 101 Patienten (57,7\u202f%) nahmen eine blutverd\u00fcnnende Therapie ein. Die Mehrheit der Patienten nahm Thrombozytenaggregationshemmer (<jats:italic>n<\/jats:italic>\u202f=\u200959; 58,4\u202f%), insbesondere ASS (<jats:italic>n<\/jats:italic>\u202f=\u200955; 54,5\u202f%) ein. Direkte orale Antikoagulanzien (DOAK) wurden von 33\u00a0Patienten (32,7\u202f%) eingenommen, darunter am h\u00e4ufigsten Apixaban (17,8\u202f%). Vitamin-K-Antagonisten (VKA) wurde von 4\u00a0Patienten (4\u202f%) eingenommen. Als h\u00e4ufigster Grund f\u00fcr eine blutverd\u00fcnnende Therapie wurde ein VHF benannt (<jats:italic>n<\/jats:italic>\u202f=\u200932, 31,7\u202f%), gefolgt von einer Stentimplantation (<jats:italic>n<\/jats:italic>\u202f=\u200920, 19,8\u202f%) und einem Schlaganfallgeschehen (<jats:italic>n<\/jats:italic>\u202f=\u200912, 11,9\u202f%); 13\u00a0Patienten (12,9\u202f%) wussten nicht, warum sie eine blutverd\u00fcnnende Therapie einnahmen. Bei 31\u00a0Patienten (30,7\u202f%) lag eine nicht eindeutig nachvollziehbare Indikation vor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>In unserer Kohorte nahm ein Gro\u00dfteil der Patienten mit AMD eine blutverd\u00fcnnende Therapie ein. Nicht bei jedem Patienten liegt jedoch eine eindeutige Indikation zur Einnahme vor. Hier sollte die Einnahme aufgrund des erh\u00f6hten Blutungsrisikos in enger Zusammenarbeit mit Haus\u00e4rzten und Kardiologen kritisch hinterfragt werden.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-024-01992-z","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T19:02:52Z","timestamp":1708023772000},"page":"216-222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Umfrage zur blutverd\u00fcnnenden Therapie bei Patienten mit altersabh\u00e4ngiger Makuladegeneration","Survey on blood thinning therapy in patients with age-related macular degeneration"],"prefix":"10.1007","volume":"121","author":[{"given":"Constance","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jezabel","family":"Tedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Husser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6352-6259","authenticated-orcid":false,"given":"Raffael","family":"Liegl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"issue":"8","key":"1992_CR1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","volume":"104","author":"JQ Li","year":"2020","unstructured":"Li\u00a0JQ et\u00a0al (2020) Prevalence and incidence of age-related macular degeneration in Europe: a\u00a0systematic review and meta-analysis. Br J Ophthalmol 104(8):1077\u20131084","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"1992_CR2","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/bjo.2010.182253","volume":"95","author":"DH Steel","year":"2011","unstructured":"Steel\u00a0DH, Sandhu\u00a0SS (2011) Submacular haemorrhages associated with neovascular age-related macular degeneration. Br J Ophthalmol 95(8):1051\u20131057","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1992_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1024\/0301-1526\/a000753","volume":"48","author":"J Pultar","year":"2019","unstructured":"Pultar\u00a0J et\u00a0al (2019) Oral antiplatelet agents in cardiovascular disease. Vasa 48(4):291\u2013302","journal-title":"Vasa"},{"issue":"22","key":"1992_CR4","first-page":"2433","volume":"125","author":"O Pelkonen","year":"2009","unstructured":"Pelkonen\u00a0O (2009) Why does acetylsalicylic acid have so many effects and applications? Duodecim 125(22):2433\u20132439","journal-title":"Duodecim"},{"issue":"5","key":"1992_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjh.14520","volume":"177","author":"MJR Desborough","year":"2017","unstructured":"Desborough\u00a0MJR, Keeling\u00a0DM (2017) The aspirin story\u2014from willow to wonder drug. Br J Haematol 177(5):674\u2013683","journal-title":"Br J Haematol"},{"key":"1992_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2018.10.008","volume":"113","author":"MR Montinari","year":"2019","unstructured":"Montinari\u00a0MR, Minelli\u00a0S, De Caterina\u00a0R (2019) The first 3500 years of aspirin history from its roots\u2014a concise summary. Curr Vasc Pharmacol 113:1\u20138","journal-title":"Curr Vasc Pharmacol"},{"issue":"9678","key":"1992_CR7","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent\u00a0C et\u00a0al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849\u20131860","journal-title":"Lancet"},{"issue":"22","key":"1992_CR8","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","volume":"124","author":"SC Smith Jr.","year":"2011","unstructured":"Smith\u00a0SC Jr. et\u00a0al (2011) AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a\u00a0guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124(22):2458\u20132473","journal-title":"Circulation"},{"issue":"3","key":"1992_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/01.CIR.0000020190.45892.75","volume":"106","author":"TA Pearson","year":"2002","unstructured":"Pearson\u00a0TA et\u00a0al (2002) AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 106(3):388\u2013391","journal-title":"Circulation"},{"issue":"8","key":"1992_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.7326\/M19-0953","volume":"171","author":"CW O\u2019Brien","year":"2019","unstructured":"O\u2019Brien\u00a0CW, Juraschek\u00a0SP, Wee\u00a0CC (2019) Prevalence of aspirin use for primary prevention of cardiovascular disease in the United States: results from the 2017 national health interview survey. Ann Intern Med 171(8):596\u2013598","journal-title":"Ann Intern Med"},{"issue":"15","key":"1992_CR11","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.121.056680","volume":"144","author":"PC Smits","year":"2021","unstructured":"Smits\u00a0PC et\u00a0al (2021) Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial. Circulation 144(15):1196\u20131211","journal-title":"Circulation"},{"issue":"3","key":"1992_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.thromres.2011.12.014","volume":"129","author":"C Becattini","year":"2012","unstructured":"Becattini\u00a0C, Vedovati\u00a0MC, Agnelli\u00a0G (2012) Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a\u00a0review of the literature. Thromb Res 129(3):392\u2013400","journal-title":"Thromb Res"},{"key":"1992_CR13","doi-asserted-by":"crossref","unstructured":"Eyileten C et\u00a0al (2020) Non-Vitamin\u00a0K Oral Anticoagulants (NOAC) Versus Vitamin\u00a0K Antagonists (VKA) for atrial fibrillation with elective or urgent percutaneous coronary intervention: a\u00a0meta-analysis with a\u00a0particular focus on combination type. J\u00a0Clin Med 9(4)","DOI":"10.3390\/jcm9041120"},{"key":"1992_CR14","doi-asserted-by":"crossref","unstructured":"Pan KL et\u00a0al (2017) Effects of non-vitamin\u00a0K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a\u00a0systematic review and meta-analysis. J\u00a0Am Heart Assoc 6(7)","DOI":"10.1161\/JAHA.117.005835"},{"issue":"11","key":"1992_CR15","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/ejhf.343","volume":"17","author":"Q Xiong","year":"2015","unstructured":"Xiong\u00a0Q et\u00a0al (2015) Non-vitamin\u00a0K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a\u00a0systemic review and meta-analysis of randomized trials. European J of Heart Fail 17(11):1192\u20131200","journal-title":"European J of Heart Fail"},{"key":"1992_CR16","doi-asserted-by":"crossref","unstructured":"Weber C et\u00a0al (2022) Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol","DOI":"10.1007\/s00417-022-05885-2"},{"issue":"2","key":"1992_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ajo.2009.08.033","volume":"149","author":"C Kuhli-Hattenbach","year":"2010","unstructured":"Kuhli-Hattenbach\u00a0C et\u00a0al (2010) Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy. Am J Ophthalmol 149(2):316\u2013321.e1","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1992_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00347-012-2567-2","volume":"109","author":"C Kuhli-Hattenbach","year":"2012","unstructured":"Kuhli-Hattenbach\u00a0C et\u00a0al (2012) Massive subretinal hemorrhage and anticoagulants. An unfortunate combination? Ophthalmologe 109(7):665\u2013669","journal-title":"Ophthalmologe"},{"issue":"2","key":"1992_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ophtha.2015.09.046","volume":"123","author":"GS Ying","year":"2016","unstructured":"Ying\u00a0GS et\u00a0al (2016) Association between antiplatelet or anticoagulant drugs and retinal or subretinal hemorrhage in the comparison of age-related macular degeneration treatments trials. Ophthalmology 123(2):352\u2013360","journal-title":"Ophthalmology"},{"issue":"10","key":"1992_CR20","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1097\/IAE.0b013e3181e2266d","volume":"30","author":"DF Kiernan","year":"2010","unstructured":"Kiernan\u00a0DF et\u00a0al (2010) Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration. Retina 30(10):1573\u20131578","journal-title":"Retina"},{"key":"1992_CR21","doi-asserted-by":"crossref","unstructured":"Storp JJ et\u00a0al (2023) Submacular hemorrhages show no significant seasonal variations in a\u00a0european cohort. J\u00a0Clin Med 12(11)","DOI":"10.3390\/jcm12113622"},{"issue":"4","key":"1992_CR22","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jacc.2006.07.009","volume":"48","author":"V Fuster","year":"2006","unstructured":"Fuster\u00a0V et\u00a0al (2006) ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation\u2014executive summary: a\u00a0report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J\u00a0Am Coll Cardiol 48(4):854\u2013906","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1992_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"GY Lip","year":"2011","unstructured":"Lip\u00a0GY et\u00a0al (2011) Comparative validation of a\u00a0novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal\/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs\/alcohol concomitantly) score. J\u00a0Am Coll Cardiol 57(2):173\u2013180","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1992_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cjca.2012.01.021","volume":"28","author":"AC Skanes","year":"2012","unstructured":"Skanes\u00a0AC et\u00a0al (2012) Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate\/rhythm control. Can J Cardiol 28(2):125\u2013136","journal-title":"Can J Cardiol"},{"issue":"5","key":"1992_CR25","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters\u00a0R et\u00a0al (2010) A\u00a0novel user-friendly score (HAS-BLED) to assess 1\u2011year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138(5):1093\u20131100","journal-title":"Chest"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-01992-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-024-01992-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-01992-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T19:03:44Z","timestamp":1709665424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-024-01992-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1992"],"URL":"https:\/\/doi.org\/10.1007\/s00347-024-01992-z","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"type":"print","value":"2731-720X"},{"type":"electronic","value":"2731-7218"}],"subject":[],"published":{"date-parts":[[2024,2,15]]},"assertion":[{"value":"17 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Weber, J.\u00a0Tedt, O.\u00a0Husser, F.G.\u00a0Holz und R.\u00a0Liegl geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}